All In Biotech

Drug Trial Radar · NCT06026917

Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)

A Single-Arm, Open-Label, Exploratory Mechanistic Validation (PoM) Clinical Trial of Toludesvenlafaxine Hydrochloride Extended-Release Tablets Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain Using 11C-CFT Positron Emission Tomography (PET)

Last checked: Nov 20, 2026Latest source record: Oct 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

15

Planned (sponsor's estimate)

Start

Sep 25, 2023

Primary completion

Jan 31, 2024

Study completion Mar 31, 2024

Sponsor

Lead sponsor
Shanghai Mental Health CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Yantai University
First posted
Sep 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was a single-arm, open-label clinical study to assess dopamine transporter occupancy in the brain of patients with depression using 11C-CFT positron emission tomography (PET).

Conditions

  • Major Depressive Disorder

Interventions

  • Toludesvenlafaxine hydrochloride sustained-release tabletsDrug

    D1\~D6, 40mg/ tablet, 1 tablet per time, once a day, D7\~D10, 80mg/ tablet, 1 tablet per time, once a day, D11\~D42, 80mg/ tablet, 2 tablets per time, once a day. For subjects who cannot tolerate 160mg, the dose may be reduced to 80mg/ dose once daily. After the number of subjects receiving 160mg/ dose reached 6, the remaining subjects received D11\~D42, 80mg/ tablet, one tablet each time, once a day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Dopamine Transporters Occupancy in the Basal Ganglia(Positron emission tomography with 11C-CFT) was determine by SUVr of the Basal Ganglia DAT.Time frame: from baseline to day 14 and 42

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Mental Health Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.